- AbCellera (ABCL, Financial) presents promising preclinical data on its PSMA x CD3 T-cell engagers at AACR 2025.
- The study shows potent in vitro and in vivo anti-tumor activity, enhancing prostate cancer treatment options.
- The T-cell engagers show potential for increased efficacy when combined with costimulatory strategies.
AbCellera Biologics Inc. (ABCL), a leader in antibody medicine discovery and development, unveiled new preclinical findings on its PSMA x CD3 T-cell engagers at the 116th Annual Meeting of the American Association for Cancer Research (AACR) in Chicago. These findings indicate that targeting prostate-specific membrane antigen (PSMA) with CD3 T-cell engagers may provide significant therapeutic advancements for treating metastatic castration-resistant prostate cancer (mCRPC).
AbCellera's preclinical data demonstrated promising activities, revealing potent tumor-cell killing in vitro, with one molecule exhibiting approximately ten times higher EC50 compared to the benchmark. The research showed sustained activity over four rounds of serial T-cell killing and significant tumor growth inhibition in a xenograft mouse model.
Furthermore, the study highlighted the potential for enhanced efficacy when these T-cell engagers are combined with costimulatory PSMA x CD28 bispecifics. According to Adam Clarke, Ph.D., SVP of Discovery at AbCellera, these findings underscore the strength of AbCellera's TCE platform strategy aimed at developing optimized therapeutic candidates by integrating diverse CD3- and tumor-binding antibodies.
AbCellera's innovative T-cell engager platform is poised to expand the therapeutic scope for cancer treatments by employing novel CD3-binding antibodies, enhancing the efficacy of therapies for difficult-to-treat cancers.
